MEI Pb Ratio vs Ev To Sales Analysis

LITS Stock

1.95 0.13 6.25%

MEI Pharma, financial indicator trend analysis is infinitely more than just investigating MEI Pharma, Common recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MEI Pharma, Common is a good investment. Please check the relationship between MEI Pharma, Pb Ratio and its Ev To Sales accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Pb Ratio vs Ev To Sales

Pb Ratio vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MEI Pharma, Common Pb Ratio account and Ev To Sales. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between MEI Pharma,'s Pb Ratio and Ev To Sales is -0.53. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of MEI Pharma, Common, assuming nothing else is changed. The correlation between historical values of MEI Pharma,'s Pb Ratio and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of MEI Pharma, Common are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Pb Ratio i.e., MEI Pharma,'s Pb Ratio and Ev To Sales go up and down completely randomly.

Correlation Coefficient

-0.53

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Pb Ratio

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from MEI Pharma,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MEI Pharma, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Selling General Administrative is likely to gain to about 20 M in 2025. Sales General And Administrative To Revenue is likely to gain to 0.66 in 2025

	2022	2023	2024	2025 (projected)
Interest Income	3.3M	3.3M	1.0M	1.9M
Net Interest Income	3.3M	3.3M	1.0M	1.9M

Interest Income Net Interest Income

MEI Pharma, fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Other Current Liab	Current Deferred Revenue	Net Debt	Cash And Short Term Investments	Net Receivables	Other Stockholder Equity	Short Term Debt
Total Assets		0.96	0.9	0.89	0.87	0.95	-0.37	0.89	-0.92	1.0	0.99	0.86	0.71	1.0	0.9	0.87	1.0	1.0	-0.92	0.87	0.93	-0.91	1.0	0.93	0.8	-0.9
Total Current Liabilities	0.96		0.81	0.95	0.72	1.0	-0.29	0.95	-0.83	0.94	0.95	0.93	0.85	0.96	0.81	0.95	0.95	0.94	-0.83	0.89	0.81	-0.77	0.94	0.81	0.87	-0.79
Total Stockholder Equity	0.9	0.81		0.63	0.88	0.83	-0.59	0.63	-0.93	0.92	0.86	0.59	0.43	0.86	1.0	0.61	0.91	0.92	-0.99	0.67	0.96	-0.92	0.91	0.96	0.65	-0.98
Property Plant And Equipment Net	0.89	0.95	0.63		0.59	0.93	-0.07	1.0	-0.71	0.85	0.91	1.0	0.92	0.92	0.63	0.99	0.87	0.86	-0.69	0.96	0.67	-0.66	0.86	0.67	0.79	-0.66
Retained Earnings	0.87	0.72	0.88	0.59		0.73	-0.66	0.59	-0.94	0.9	0.85	0.55	0.42	0.84	0.88	0.56	0.88	0.89	-0.87	0.6	0.93	-0.89	0.88	0.92	0.69	-0.87
Accounts Payable	0.95	1.0	0.83	0.93	0.73		-0.34	0.93	-0.83	0.94	0.93	0.9	0.84	0.95	0.83	0.93	0.95	0.93	-0.83	0.86	0.81	-0.76	0.92	0.81	0.89	-0.79
Cash	-0.37	-0.29	-0.59	-0.07	-0.66	-0.34		-0.07	0.67	-0.45	-0.31	-0.02	-0.14	-0.31	-0.59	-0.1	-0.39	-0.4	0.54	-0.1	-0.46	0.36	-0.36	-0.46	-0.46	0.51
Non Current Assets Total	0.89	0.95	0.63	1.0	0.59	0.93	-0.07		-0.71	0.85	0.91	1.0	0.92	0.92	0.63	0.99	0.87	0.86	-0.69	0.96	0.67	-0.66	0.86	0.67	0.79	-0.66
Common Stock Shares Outstanding	-0.92	-0.83	-0.93	-0.71	-0.94	-0.83	0.67	-0.71		-0.95	-0.9	-0.68	-0.58	-0.9	-0.93	-0.69	-0.93	-0.93	0.96	-0.76	-0.92	0.88	-0.92	-0.91	-0.72	0.94
Short Term Investments	1.0	0.94	0.92	0.85	0.9	0.94	-0.45	0.85	-0.95		0.98	0.82	0.69	0.98	0.92	0.83	1.0	1.0	-0.94	0.84	0.95	-0.91	0.99	0.94	0.81	-0.92
Non Current Liabilities Total	0.99	0.95	0.86	0.91	0.85	0.93	-0.31	0.91	-0.9	0.98		0.89	0.73	1.0	0.86	0.88	0.99	0.99	-0.9	0.9	0.91	-0.9	0.99	0.91	0.77	-0.89
Capital Lease Obligations	0.86	0.93	0.59	1.0	0.55	0.9	-0.02	1.0	-0.68	0.82	0.89		0.92	0.9	0.59	0.99	0.85	0.83	-0.66	0.96	0.63	-0.63	0.84	0.63	0.76	-0.62
Other Current Assets	0.71	0.85	0.43	0.92	0.42	0.84	-0.14	0.92	-0.58	0.69	0.73	0.92		0.75	0.43	0.95	0.69	0.67	-0.48	0.84	0.42	-0.37	0.66	0.41	0.83	-0.42
Total Liab	1.0	0.96	0.86	0.92	0.84	0.95	-0.31	0.92	-0.9	0.98	1.0	0.9	0.75		0.86	0.9	0.99	0.99	-0.9	0.91	0.91	-0.89	0.99	0.9	0.79	-0.88
Net Invested Capital	0.9	0.81	1.0	0.63	0.88	0.83	-0.59	0.63	-0.93	0.92	0.86	0.59	0.43	0.86		0.61	0.91	0.92	-0.99	0.67	0.96	-0.92	0.91	0.96	0.65	-0.98
Property Plant And Equipment Gross	0.87	0.95	0.61	0.99	0.56	0.93	-0.1	0.99	-0.69	0.83	0.88	0.99	0.95	0.9	0.61		0.85	0.83	-0.67	0.94	0.63	-0.61	0.83	0.63	0.82	-0.62
Total Current Assets	1.0	0.95	0.91	0.87	0.88	0.95	-0.39	0.87	-0.93	1.0	0.99	0.85	0.69	0.99	0.91	0.85		1.0	-0.93	0.86	0.94	-0.92	1.0	0.94	0.79	-0.91
Net Working Capital	1.0	0.94	0.92	0.86	0.89	0.93	-0.4	0.86	-0.93	1.0	0.99	0.83	0.67	0.99	0.92	0.83	1.0		-0.94	0.85	0.95	-0.93	1.0	0.95	0.78	-0.92
Short Long Term Debt Total	-0.92	-0.83	-0.99	-0.69	-0.87	-0.83	0.54	-0.69	0.96	-0.94	-0.9	-0.66	-0.48	-0.9	-0.99	-0.67	-0.93	-0.94		-0.76	-0.96	0.94	-0.93	-0.96	-0.61	1.0
Other Current Liab	0.87	0.89	0.67	0.96	0.6	0.86	-0.1	0.96	-0.76	0.84	0.9	0.96	0.84	0.91	0.67	0.94	0.86	0.85	-0.76		0.69	-0.71	0.86	0.68	0.63	-0.73
Current Deferred Revenue	0.93	0.81	0.96	0.67	0.93	0.81	-0.46	0.67	-0.92	0.95	0.91	0.63	0.42	0.91	0.96	0.63	0.94	0.95	-0.96	0.69		-0.99	0.95	1.0	0.63	-0.96
Net Debt	-0.91	-0.77	-0.92	-0.66	-0.89	-0.76	0.36	-0.66	0.88	-0.91	-0.9	-0.63	-0.37	-0.89	-0.92	-0.61	-0.92	-0.93	0.94	-0.71	-0.99		-0.94	-0.99	-0.53	0.96
Cash And Short Term Investments	1.0	0.94	0.91	0.86	0.88	0.92	-0.36	0.86	-0.92	0.99	0.99	0.84	0.66	0.99	0.91	0.83	1.0	1.0	-0.93	0.86	0.95	-0.94		0.95	0.76	-0.92
Net Receivables	0.93	0.81	0.96	0.67	0.92	0.81	-0.46	0.67	-0.91	0.94	0.91	0.63	0.41	0.9	0.96	0.63	0.94	0.95	-0.96	0.68	1.0	-0.99	0.95		0.63	-0.96
Other Stockholder Equity	0.8	0.87	0.65	0.79	0.69	0.89	-0.46	0.79	-0.72	0.81	0.77	0.76	0.83	0.79	0.65	0.82	0.79	0.78	-0.61	0.63	0.63	-0.53	0.76	0.63		-0.55
Short Term Debt	-0.9	-0.79	-0.98	-0.66	-0.87	-0.79	0.51	-0.66	0.94	-0.92	-0.89	-0.62	-0.42	-0.88	-0.98	-0.62	-0.91	-0.92	1.0	-0.73	-0.96	0.96	-0.92	-0.96	-0.55

Click cells to compare fundamentals

MEI Pharma, Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for MEI Stock Analysis

When running MEI Pharma,'s price analysis, check to measure MEI Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma, is operating at the current time. Most of MEI Pharma,'s value examination focuses on studying past and present price action to predict the probability of MEI Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma,'s price. Additionally, you may evaluate how the addition of MEI Pharma, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

MEI Pb Ratio vs Ev To Sales Analysis

Pb Ratio vs Ev To Sales

Pb Ratio vs Ev To Sales Correlation Analysis

Correlation Coefficient

Pb Ratio

Ev To Sales

MEI Pharma, fundamental ratios Correlations

MEI Pharma, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for MEI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Investments	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities

Net Receivables	- 0.99	Net Debt
Net Debt	- 0.99	Current Deferred Revenue
Short Long Term Debt Total	- 0.99	Net Invested Capital
Short Long Term Debt Total	- 0.99	Total Stockholder Equity
Short Term Debt	- 0.98	Net Invested Capital
Short Term Debt	- 0.98	Total Stockholder Equity